Edgewise Therapeutics (EWTX) Other Working Capital Changes (2022 - 2026)
Edgewise Therapeutics (EWTX) reported Other Working Capital Changes of -$196000.0 for Q1 2026, down 9.5% on a YoY basis from -$216567.9 in Q1 2025, and down 1.55% sequentially from -$193000.0 in Q4 2025.
Edgewise Therapeutics (EWTX) Other Working Capital Changes (2022 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 5 years of Other Working Capital Changes data on file, last reported at -$196000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Working Capital Changes fell 9.5% year-over-year to -$196000.0; the trailing twelve-month figure through Mar 2026 stood at -$765000.0 (down 225.53% YoY), and the FY2025 full-year result was -$748000.0, down 240.0% from the prior year.
- Other Working Capital Changes slipped to -$196000.0 in Q1 2026, from -$193000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $2.7 million in Q4 2025 to a low of -$3.0 million in Q1 2026.
- A 5-year average of $390058.8 and a median of $359000.0 in 2023 frame the typical range for Other Working Capital Changes.
- Across the five-year window, Other Working Capital Changes jumped 383.33% in 2023 and slumped 241.38% in 2024, its largest moves.
- Tracing EWTX's Other Working Capital Changes over 5 years: stood at $1.8 million in 2022, then tumbled by 106.58% to -$117000.0 in 2023, then jumped by 351.28% to $294000.0 in 2024, then slumped by 165.65% to -$193000.0 in 2025, then slipped by 1.55% to -$196000.0 in 2026.
- Business Quant data shows EWTX's Other Working Capital Changes at -$196000.0 in Q1 2026, -$193000.0 in Q4 2025, and -$189000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -196,000.00 |
| Mar 31, 2026 | -196,000.00 |
| Mar 31, 2026 | -196,000.00 |
| Dec 31, 2025 | -193,000.00 |
| Dec 31, 2025 | -193,000.00 |
| Dec 31, 2025 | -193,000.00 |
| Sep 30, 2025 | -189,000.00 |
| Sep 30, 2025 | -189,000.00 |
| Sep 30, 2025 | -189,000.00 |
| Jun 30, 2025 | -187,000.00 |
| Jun 30, 2025 | -187,000.00 |
| Jun 30, 2025 | -187,000.00 |
| Mar 31, 2025 | -179,000.00 |
| Mar 31, 2025 | -179,000.00 |
| Mar 31, 2025 | -179,000.00 |
| Dec 31, 2024 | 294,000.00 |
| Dec 31, 2024 | 294,000.00 |
| Dec 31, 2024 | 294,000.00 |
| Sep 30, 2024 | -179,000.00 |
| Sep 30, 2024 | -179,000.00 |